Ovarian Hyperstimulation Syndrome Due to a Mutation in the Follicle-Stimulating Hormone Receptor

Abstract

The ovarian hyperstimulation syndrome most often occurs as an iatrogenic complication of ovarian-stimulation treatments for in vitro fertilization (the incidence of severe forms ranges from 0.5 to 5 percent).1 The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration in a third space.2 Although the presence of human chorionic gonadotropin is invariably associated with the condition, the pathophysiological mechanism remains undefined.3 The overproduction of endogenous chorionic gonadotropin during pregnancy has been associated with spontaneous ovarian hyperstimulation syndrome (also termed hyperreactio luteinalis of the first trimester), as well as with . . .